Axillary Hyperhidrosis

What is axillary hyperhidrosis?
Primary axillary hyperhidrosis is a medical condition which involves overactive sweat glands and leads to excessive underarm sweating. Sweat is your body's temperature regulator. In primary axillary hyperhidrosis, sweating significantly exceeds the body's normal requirements for cooling. Sweating can also occur in excess on the upper lip,  palms of the hands and the soles of the feet.

Can BOTOX® treatment help?
BOTOX® is FDA approved for excessive underarm sweating that is not adequately managed with topical agents. BOTOX® neurotoxin treatment helps control this condition by temporarily blocking the chemical signals from the nerves that stimulate the sweat glands. When the sweat glands don't receive chemical signals, the excessive sweating stops.
You should notice a significant reduction in underarm sweating within 4 weeks of your first treatment. If you are still sweating, there is a possibility that some sweat glands may have been missed, and you may continue to experience some sweating from the untreated areas. If you do not see a significant reduction in sweating, you should contact us at the clinic and request a follow-up consultation. Studies have shown treatment effects to last on average nine months.


For more information about excessive underarm sweating, visit the International Hyperhidrosis Society Web site at www.SweatHelp.org or www.botoxseveresweating.com.

BOTOX® is indicated for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents.

Important Safety Information

Contraindications
BOTOX® treatment is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any ingredient in the formulation.

Warnings
The recommended dosage and frequency of administration for BOTOX® should not be exceeded. Risks resulting from administration at higher dosages are not known. Serious and/or immediate hypersensitivity reactions have been rarely reported. These reactions include anaphylaxis, urticaria, soft tissue edema, and dyspnea. If such a reaction occurs, further BOTOX® injection should be discontinued and appropriate medical therapy immediately instituted. BOTOX® should only be diluted with 0.9% nonpreserved sodium chloride.
Individuals with peripheral motor neuropathic diseases (eg, amyotrophic lateral sclerosis or motor neuropathy) or neuromuscular junctional disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) should only receive BOTOX® with caution. Patients with neuromuscular disorders may be at increased risk of clinically significant systemic effects including severe dysphagia and respiratory compromise from typical doses of BOTOX®.

Precautions
Patients should be evaluated for potential causes of secondary hyperhidrosis (eg, hyperthyroidism) to avoid symptomatic treatment of hyperhidrosis without the diagnosis and/or treatment of the underlying disease.
The effect of administering different botulinum neurotoxin serotypes at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.
There are no adequate and well-controlled studies of BOTOX® treatment in pregnant women. BOTOX® should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risks, including abortion or fetal malformations, which have been observed in rabbits.

Adverse reactions
There have been rare reports of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors including cardiovascular disease. The exact relationship of these events to the botulinum toxin injection has not been established.
The most frequently reported adverse events (3% to 10% of patients) following BOTOX® injection for severe primary axillary hyperhidrosis included injection-site pain and hemorrhage, non-axillary sweating, infection, pharyngitis, flu syndrome, headache, fever, neck or back pain, pruritus, and anxiety.

BOTOX® is a registered trademark of Allergan, Inc.
Allergan Australia Pty Ltd. ABN 85 000 612 831, 77 Ridge Street, Gordon, NSW 2072.
Allergan New Zealand Ltd, PO Box 1873 Auckland 1000, New Zealand